Vitiligo: depigmented patches, autoimmunity, and treatment in AU

What vitiligo is — and why it matters beyond skin

Vitiligo is an autoimmune skin condition in which the immune system destroys melanocytes — the specialised cells that produce melanin and give skin, hair, and mucous membranes their colour. The result is well-defined depigmented (white) patches that can appear on any body surface, most commonly the face, hands, wrists, genitalia, and skin around body openings.

It affects approximately 1% of the world’s population, including an estimated 250,000 Australians. Prevalence is equal across sexes and all skin colours, though the visible contrast is more pronounced — and the psychosocial impact often more severe — in people with darker skin tones. Onset follows a bimodal pattern: a childhood or adolescent peak and a second peak in the twenties and thirties.

Vitiligo is not merely a cosmetic concern. It signals immune dysregulation warranting investigation for associated autoimmune conditions, and it carries a documented mental health burden that deserves as much clinical attention as the skin findings themselves. The general practice role encompasses accurate diagnosis, activity assessment, initiating appropriate first-line treatment, systematic comorbidity screening, and timely dermatology referral when needed.

A. Core clinical — the AU general practice framework

Classifying the type

The Vitiligo Global Issues Consensus Conference (VGICC) recognises two main forms:

Non-segmental vitiligo (NSV) accounts for roughly 90% of cases. Patches are bilateral and tend toward symmetry. Subtypes include generalised (any body site), acrofacial (hands, feet, periorificial face), mucosal (lips, genitalia), and universal (over 80% body surface area). NSV has a strong autoimmune comorbidity association and may progress over many years.

Segmental vitiligo (SV) is unilateral and typically follows a dermatomal distribution. It is more common in children and adolescents and generally stabilises after one to two years of initial spread. Autoimmune comorbidity association is weaker than in NSV.

Assessing activity — the most important clinical step

Distinguishing active from stable vitiligo directly guides treatment decisions and referral urgency.

Signs of active disease:

• Koebner phenomenon — new depigmented patches appearing at sites of skin trauma (cuts, pressure, friction, surgical scars)
• Confetti depigmentation — small white spots spreading centrifugally around existing patches
• Hypochromic borders — fading, indistinct patch edges indicating expansion
• Leukotrichia — white hairs within a patch (indicates deep follicular melanocyte involvement; predicts poorer repigmentation)
• Trichrome vitiligo — a transitional band of intermediate colour between normal and depigmented skin

Stable disease is defined as no new lesions and no expansion for at least one year. Surgical treatment options require stability.

Clinical assessment in general practice

History to take:

• Duration and distribution — when patches first appeared, which sites, speed of spread
• Trigger history — trauma, emotional stress, severe sunburn, pregnancy, medications
• Autoimmune personal and family history — thyroid disease, type 1 diabetes, Addison’s disease, alopecia areata, pernicious anaemia
• Psychosocial impact — quality of life, occupation (outdoor sun exposure), school engagement in children and adolescents
• Prior treatments — topical steroids, calcineurin inhibitors, UV exposure history

Physical examination:

• Distribution and estimated body surface area of depigmented patches
• Wood’s lamp assessment — vivid blue-white fluorescence confirms melanocyte absence; most useful in fair-skinned patients and uncertain diagnoses
• Activity signs (above)
• Halo naevi — associated with vitiligo activity
• Thyroid examination; blood pressure if Addison’s disease is suspected clinically

Investigations at diagnosis

Per eTG and Australasian College of Dermatologists guidance:

• TSH — mandatory at diagnosis; recheck annually or biannually thereafter
• Anti-TPO antibodies — at least once at diagnosis to establish baseline thyroid autoimmunity risk
• Fasting glucose or HbA1c — type 1 diabetes screening
• Full blood count + B12 + folate — pernicious anaemia secondary to autoimmune gastric atrophy
• Broader panel (morning cortisol, anti-adrenal antibody, ANA) if symptoms suggest additional autoimmune disease

Biopsy is rarely required — vitiligo is a clinical diagnosis. When performed, histology shows absent melanocytes at the dermoepidermal junction with minimal inflammation.

B. Treatment evidence — what works, what doesn’t, and what is emerging

Topical treatments — first-line for localised disease

Topical corticosteroids are the most widely used first-line treatment for localised vitiligo. The Cochrane systematic review of interventions for vitiligo confirms their effectiveness for inducing repigmentation on the trunk, limbs, and face when applied in appropriate formulations and intermittent regimens.

Prescribing principles per eTG:

• Potent formulations (mometasone furoate 0.1%, betamethasone valerate 0.05%) for trunk and limbs — applied once daily in an intermittent regimen (for example, 2 weeks on, 2 weeks off) to limit skin atrophy and systemic absorption
• Mild formulations (hydrocortisone 1–2.5%) for the face in children; short courses only on facial skin
• Monitor for skin atrophy, telangiectasia, and striae with prolonged use, particularly on the face and flexural sites

Topical calcineurin inhibitors (TCIs) — tacrolimus 0.1% ointment (Protopic) and pimecrolimus 1% cream — are preferred over corticosteroids for facial and flexural vitiligo to avoid steroid-related skin atrophy. Multiple randomised controlled trials confirm comparable repigmentation rates to potent topical steroids on the face. These agents are PBS-listed for atopic dermatitis; vitiligo use is off-label but widely accepted in Australian dermatology practice.

Phototherapy — gold standard for widespread disease

Narrowband UVB (NB-UVB) phototherapy at 311 nm is the most rigorously evaluated treatment for widespread vitiligo, supported by the strongest trial data, delivered as two to three sessions per week for six to twelve months. Cochrane-level evidence supports significant repigmentation in 50–75% of patients who complete an adequate course. Best response sites are the face and neck (up to 90%); hands and feet respond less reliably (20–30%).

Key patient counselling points:

• Repigmentation is gradual — first signs typically appear after three to four months of consistent treatment
• Completing the full course matters; premature discontinuation substantially reduces outcomes
• NB-UVB is available through phototherapy units at major dermatology departments across Australia

Excimer laser (308 nm) delivers targeted NB-UVB to localised stable patches with excellent face and scalp response rates; available at specialist dermatology centres privately.

PUVA (psoralen plus UVA) has been largely superseded by NB-UVB given equivalent or inferior efficacy and higher carcinogenicity risk.

JAK inhibitor ruxolitinib cream — FDA-approved, not yet in Australia

The TRuE-V1 and TRuE-V2 phase 3 trials (Rosmarin NEJM 2022) demonstrated that ruxolitinib 1.5% cream (Opzelura) applied twice daily achieved VASI75 (≥75% improvement in the Facial Vitiligo Area Scoring Index) in approximately 30% of patients at 24 weeks, rising to around 50% at 52 weeks. These are meaningful results for a condition with historically limited options.

Australian regulatory position: ruxolitinib cream received FDA approval in 2022 for non-segmental vitiligo in patients aged 12 years and over. As of September 2026, it has not received TGA approval and is not PBS-listed in Australia. Access requires a Special Access Scheme Category A (SAS-A) application; private costs are substantial. Patients enquiring about this treatment should be told clearly: compelling evidence exists; the treatment is not yet available through standard Australian prescribing pathways.

Systemic treatments

For rapidly active spreading disease, oral mini-pulse betamethasone (5 mg on two consecutive days per week) can halt progression; this is a specialist-initiated treatment requiring monitoring for weight gain, mood effects, and glucose. Methotrexate and cyclosporine are used in refractory active cases under specialist supervision. Oral JAK inhibitors (tofacitinib, baricitinib) are emerging but carry significant systemic risk and are not standard of care.

Surgical options (stable disease only)

Melanocyte-keratinocyte transplant procedures (MKTP), split-thickness grafting, suction blister grafting, and punch grafting are reserved for patients with stable segmental or localised vitiligo unresponsive to medical treatment. These are specialist surgical dermatology procedures with excellent outcomes in selected patients.

C. Comorbidities, photoprotection, and mental health

Autoimmune comorbidity screening

Vitiligo belongs to the autoimmune polyglandular syndrome spectrum. The Australasian College of Dermatologists recommends systematic screening at diagnosis and ongoing surveillance:

Investigation	Frequency	Rationale
TSH ± anti-TPO	At diagnosis; then 1–2 yearly	Autoimmune thyroid disease in ~15%
Fasting glucose or HbA1c	At diagnosis; 1–2 yearly	Type 1 diabetes elevated risk
FBC + B12 + folate	At diagnosis	Pernicious anaemia (autoimmune gastric atrophy)
Broader panel (morning cortisol, ANA)	If symptomatic	Addison’s disease, SLE, other

Do not wait for symptoms before beginning comorbidity screening — many associated autoimmune conditions have insidious onset.

Photoprotection

Depigmented skin contains no melanin and provides no intrinsic protection against UV radiation. In Australia’s UV environment, this carries real clinical consequences:

• Apply broad-spectrum SPF 50+ sunscreen to depigmented patches daily
• Sun-protective clothing (long sleeves, wide-brim hats) for outdoor workers and everyday sun exposure
• Sunburn over depigmented patches risks Koebner-triggered lesion expansion; counsel patients specifically on this mechanism
• Melanoma risk in vitiligo patches is theoretically reduced (no melanocytes) but surrounding normal skin retains full risk — consistent SunSmart habits apply

Mental health assessment and support

Studies of Australians with vitiligo and international data consistently show elevated rates of depression (up to 35%), anxiety, and clinically significant body-image distress. The psychosocial burden is highest in:

• People with darker skin types (Fitzpatrick IV–VI) where the contrast is starkest
• Exposed sites — face, hands, neck
• Children and adolescents facing stigma and bullying
• Patients with progressive active disease

Incorporate a validated screen (PHQ-9, K10) at every review and ask directly about quality of life impact. A Mental Health Treatment Plan (MBS items 2715/2717) provides access to up to ten subsidised psychology sessions annually. Cosmetic camouflage (Dermablend, Cover FX) and dihydroxyacetone (DHA) self-tanners are non-medical but genuinely impactful for day-to-day quality of life and deserve mention at every consultation.

D. Australian operations

MBS items

• Item 23 — standard GP attendance (Level B)
• Items 36/44 — Level C/D consultations for comorbidity screening and treatment planning
• Item 132/133 — dermatology specialist initial/subsequent attendance
• Item 30187/30189 — therapeutic UV light treatment session/course
• Item 30196 — laser treatment (excimer)
• Items 2715/2717 — Mental Health Treatment Plan (GP-initiated)
• Items 80000–80020 — psychology Better Access sessions
• Item 715 — Aboriginal and Torres Strait Islander Health Assessment

PBS prescribing

• Topical corticosteroids (mometasone furoate, betamethasone valerate, clobetasol propionate) — PBS General Schedule; widely available
• Tacrolimus 0.1% ointment (Protopic) — PBS listed for atopic dermatitis; off-label for vitiligo but widely prescribed in dermatology practice
• Ruxolitinib cream (Opzelura) — not TGA-approved, not PBS-listed (September 2026); SAS-A private access only at significant cost
• Oral betamethasone — General Schedule; specialist initiation for mini-pulse regimens
• Methotrexate — Authority Required; dermatology-initiated

Referral pathways

• Dermatology — widespread NSV requiring phototherapy; rapidly active disease; stable segmental disease for surgical candidacy; complex or refractory cases
• Phototherapy unit — typically via dermatology referral; available at major public hospital departments
• Paediatric dermatology — children with active disease or significant psychosocial impact
• Endocrinology — confirmed autoimmune comorbidities or suspected Addison’s disease
• Psychology/psychiatry — significant depression, body dysmorphic features, or self-harm risk

Australian patient resources

• Vitiligo Association of Australia — peer support, national community, education
• Australasian College of Dermatologists — find a dermatologist
• HealthDirect — Vitiligo
• Better Health Channel — general skin health
• DermNet NZ — Vitiligo — comprehensive patient and clinician resource

E. Special populations

Children and adolescents

Vitiligo onset in childhood carries a disproportionate psychosocial burden. Bullying, social stigma, and identity distress are well-documented. Treatment decisions must balance the benefit of early repigmentation against the risk of steroid atrophy on young skin — calcineurin inhibitors are often preferred for facial disease in children to avoid this complication.

Segmental vitiligo is more common in this age group and carries a different prognosis: most cases stabilise after the initial spread phase. Parents benefit from counselling about this natural history rather than assuming long-term progressive disease.

School liaison, early peer support referral, and proactive psychology referral should be offered without waiting for a crisis.

Pregnancy

Vitiligo does not affect pregnancy outcomes. Topical agents require consideration: brief courses of mild-to-moderate potency corticosteroids are generally acceptable for limited disease during pregnancy; prolonged use and high-potency formulations warrant specialist input. eTG covers topical steroid safety in pregnancy in detail. NB-UVB phototherapy has a good safety profile in pregnancy; systemic treatments are generally deferred until after birth.

Darker skin types (Fitzpatrick IV–VI)

Vitiligo affects all skin types equally, but visibility and psychosocial impact are substantially greater in patients with Fitzpatrick types IV–VI where the contrast is stark. Cultural dimensions of skin colour in some communities compound this further. Clinicians should proactively discuss cosmetic camouflage, phototherapy access, and mental health support, and not underestimate impact by framing the condition as “only cosmetic.”

Older adults

The autoimmune polyglandular conditions associated with vitiligo are more prevalent with advancing age, making comorbidity review especially important. Annual thyroid function and diabetes screening remains appropriate. The Koebner phenomenon may be triggered by pressure sores, repeated trauma sites, or common skin procedures in older patients.

When to escalate

Refer to dermatology or escalate urgently when:

• Widespread NSV requiring narrowband UVB phototherapy initiation
• Rapidly progressive active disease unresponsive to topical treatment — oral mini-pulse betamethasone is a specialist decision
• Child with active disease or significant psychosocial distress
• Stable segmental disease unresponsive to topical treatment — assess for surgical candidacy
• Features suggesting Addison’s disease (postural hypotension, fatigue, hyperpigmentation, hyponatraemia) — urgent endocrinology
• Confirmed autoimmune thyroid disease, type 1 diabetes, or pernicious anaemia requiring co-management
• Clinically significant depression, body dysmorphic features, or self-harm risk — mental health referral
• Diagnostic uncertainty — consider dermoscopy, biopsy, or specialist review

What this article is and is not

This is general health information drawn from Australian clinical resources — Therapeutic Guidelines (eTG), Australasian College of Dermatologists, RACGP, and peer-reviewed trial data — for educational purposes. It does not constitute personal medical advice and does not create a doctor–patient relationship. Treatment decisions for vitiligo depend on type, activity, extent, skin type, patient preferences, and access to specialist services; these require assessment by your own GP and, where appropriate, a dermatologist.

For Australian consumer information: HealthDirect — Vitiligo, Vitiligo Association of Australia, Better Health Channel, DermNet NZ — Vitiligo.

For mental health crisis support: Lifeline 13 11 14, Beyond Blue 1300 22 4636, 13YARN 13 92 76 (First Nations support).

---

Sources cited

1. Australasian College of Dermatologists — Vitiligo
2. Therapeutic Guidelines (eTG) — Vitiligo and pigmentary disorders
3. RACGP — Skin conditions in general practice
4. Cochrane — Interventions for vitiligo
5. Ezzedine K et al. — Vitiligo (Lancet 2015)
6. Rosmarin D et al. — Ruxolitinib cream TRuE-V1 and V2 (NEJM 2022)
7. British Association of Dermatologists — Vitiligo guidelines (Eleftheriadou JEADV 2022)
8. TGA — Therapeutic Goods Administration
9. Vitiligo Association of Australia
10. HealthDirect — Vitiligo
11. DermNet NZ — Vitiligo